Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease.

Scientific reports - 14 Oct 2020

Gonzalez-Hunt C P, Thacker E A, Toste C M, Boularand S, Deprets S, Dubois L, Sanders L H

Abstract excerpt

Leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for the treatment of Parkinson's disease (PD) and LRRK2 kinase inhibitors are currently being tested in early phase clinical trials. In order to ensure the highest chance of success, a biomarker-guided entry into clinical trials is key. LRRK2 phosphorylation, and phosphorylation of the LRRK2 substrate Rab10, have been proposed as target...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Damage
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Lymphocytes

Share to Mitochondria

Share to Molecular Targeted Therapy

Share to Parkinson Disease

Source

Open in PubMed Open full text

Identifiers

PMID: 33057100
DOI: 10.1038/s41598-020-74195-6
PMCID: PMC7557909

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease.PMID 33057100Read ↗

A blood-based marker of mitochondrial DNA damage in Parkinson’s diseaseSemantic proximity Read ↗

G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damageSemantic proximity Read ↗

A mitochondrial blood-based patient stratification candidate biomarker for Parkinson’s diseaseSemantic proximity Read ↗

Recent advances in targeting LRRK2 for Parkinson's disease treatment.Semantic proximity Read ↗

Mitochondrial Mechanisms of LRRK2 G2019S PenetranceSemantic proximity Read ↗

The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson’s DiseaseSemantic proximity Read ↗

LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.Semantic proximity Read ↗

Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation.Semantic proximity Read ↗

An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 CohortsSemantic proximity Read ↗

Mitochondrial DNA Deletions Discriminate Affected from Unaffected LRRK2 Mutation CarriersSemantic proximity Read ↗

Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils.Semantic proximity Read ↗

LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to Mycobacterium tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.